B16-F10 / B16-F10-luc Orthotopic Mouse Model Service for Melanoma

The B16-F10 / B16-F10-luc orthotopic mouse model of melanoma engrafts the most widely used metastatic murine melanoma directly into the skin site, pairing aggressive pigmented tumor growth and spontaneous lung metastasis with quantitative luciferase bioluminescence in a fully immunocompetent host. Alfa Cytology delivers this platform as an end-to-end preclinical service: authenticated CRL-6475 banking, luciferase line qualification, intradermal or flank engraftment in C57BL/6 recipients, scheduled whole-body imaging, checkpoint/vaccine/cell-therapy dosing, and endpoints spanning tumor metrics, metastasis counting, immune profiling, and histopathology.

Overview of B16-F10 / B16-F10-luc Orthotopic Mouse Model for Melanoma

B16-F10 descends from the B16 melanoma that arose spontaneously behind the ear of a C57BL/6J mouse at The Jackson Laboratory in 1954. Its modern identity was forged by Isaiah Fidler, who in 1973 reported the selection of successive tumor lines for metastasis: after ten serial cycles of intravenous inoculation, lung-colony recovery, and re-expansion in syngeneic C57BL/6 mice, the tenth-passage subclone — B16-F10 — emerged with the highest lung-colonizing potential of the series, a property Fidler showed to be stable through many passages. The selection logic became textbook metastasis biology: 99% of intravenously injected B16 cells perish within a day, and only a small cohort of roughly 400 cells successfully arrests and colonizes the lung. B16-F10 is a pigmented, melanin-producing line expressing the full melanocyte differentiation antigen set — gp100/pmel17, tyrosinase, TRP-1, TRP-2, and the MART-1 homolog — with the TRP-2 181-188 peptide (VYDFFVWL) on H-2Kb characterized as a bona fide tumor-rejection antigen. Its molecular profile carries inactivating lesions in CDKN2A, PTEN, and TP53, but few activating mutations in BRAF, KIT, KRAS, or NRAS — a genotype that keeps the model’s value firmly in immunology rather than targeted-kinase pharmacology.

Fig 1. After surgical resection of the auricular cartilage, a blood clot containing B16-F10 cells was implanted into the auricle, resulting in a tumor formation rate of 95%. (Potez, Marine, et al., 2018)

What defines B16-F10 as an immunotherapy substrate is its deliberate coldness: basal MHC class I expression is low (inducible by IFN-γ), tumor-specific CTLs are difficult to expand from B16 biopsies, and checkpoint blockade alone typically has modest effects — precisely the resistance phenotype that makes the model the field’s toughest benchmark for immunotherapeutic efficacy. Luciferase-tagged derivatives (B16-F10-luc, B16F10-luc2) enable non-invasive bioluminescence tracking of primary tumor growth and metastatic outgrowth after D-luciferin administration, complementing caliper measurements. Engraftment is flexible: intradermal inoculation recreates the orthotopic skin site, flank injection supports standard efficacy cohorts with lymphatic and pulmonary metastatic tendencies, and tail-vein delivery produces the classic experimental lung-metastasis assay used since Fidler’s original work. Together with companion reagents — pmel-1 TCR-transgenic T cells against gp100, TRP-2 peptide vaccines, GM-CSF-secreting vaccine lines — the B16-F10-luc orthotopic platform underpins vaccine, checkpoint, adoptive-cell-therapy, oncolytic-virus, and nanoparticle programs in melanoma research.

Cell Line Information: B16-F10 / B16-F10-luc

B16-F10 is the most frequently used syngeneic melanoma line in oncoimmunology, combining Fidler-class metastatic potency with a complete melanocyte antigen repertoire. Its luciferase derivative extends it into imaging-guided studies. Core attributes follow.

Our Services

B16-F10’s value as a cold-tumor benchmark depends on consistency that many laboratories quietly lose over serial passage — pigmentation, antigen expression, and metastatic potency all drift with mishandling. Alfa Cytology guards these traits the way the field’s landmark studies demanded: authenticated CRL-6475 master banks, restricted in vitro passage before animal use, luciferase lots released only after uniform glow is confirmed, and in vivo passage history documented. Engraftment follows written routes — intradermal, flank, or tail-vein lung-colony — with dosing schedules aligned to checkpoint, vaccine, or adoptive-cell designs. Through imaging, metastasis counting, immune profiling, and histopathology, Alfa Cytology runs the entire B16-F10 / B16-F10-luc orthotopic workflow as one accountable preclinical program.

Workflow of B16-F10 / B16-F10-luc Orthotopic Mouse Model Construction

The B16-F10-luc orthotopic workflow is organized around three engraftment routes and a shared imaging-and-immunology spine. The sequence below covers construction and execution for each study design.

1. Line stewardship and reporter release: B16-F10 / B16-F10-luc stocks are expanded from authenticated master banks within restricted passage counts, mycoplasma-tested, pigmentation verified, and released only after uniform firefly luciferase expression is confirmed in vitro.
2. Inoculum preparation: Log-phase adherent cultures are released with trypsin/EDTA, washed, counted, and resuspended in sterile PBS at the study dose (commonly 1×10⁵ to 2×10⁵ cells in 50-100 µL for intradermal or flank routes).
3. Recipient preparation: Syngeneic C57BL/6 mice are acclimatized, body-weight stratified, and shaved at the engraftment site; pmel-1 or other donor mice are staged in parallel for adoptive-cell designs.
4. Route-specific engraftment: Cells are delivered intradermally for the orthotopic skin site, subcutaneously for flank efficacy cohorts, or via the tail vein for the experimental lung-metastasis assay; baseline bioluminescence after D-luciferin confirms engraftment and starting burden.
5. Randomization and treatment allocation: Once tumors reach defined size or signal, mice are randomized into arms — checkpoint antibodies, vaccines, oncolytic viruses, adoptive pmel-1 T cells, nanoparticles, or combinations — with matched baselines across groups.
6. Longitudinal monitoring: Caliper measurements and serial bioluminescence track primary growth twice weekly, body weight and clinical condition are scored throughout, and in metastatic designs organs are imaged ex vivo at interim points where designs require.
7. Endpoint analysis: At termination, primary tumors are excised and weighed, lungs are inflated, inspected, and metastatic nodules counted (and imaged ex vivo for luciferase arms), spleens and draining lymph nodes are processed for immune profiling by flow cytometry, and tissues are preserved for histopathology and melanin confirmation.

Fig 2. B16-F10 / B16-F10-luc orthotopic mouse model construction workflow.

Case Study-B16-F10 / B16-F10-luc Orthotopic Mouse Model Development

Alfa Cytology has implemented the B16-F10 orthotopic platform in preclinical programs spanning checkpoint-inhibitor benchmarking, therapeutic vaccines, oncolytic viruses, and adoptive cell therapies in the cold-tumor setting. In these studies, caliper and bioluminescence readouts tracked primary tumor growth and metastatic outgrowth on synchronized schedules, route-specific designs — intradermal, flank, and tail-vein lung-colony — were matched to program questions, and terminal analyses combined lung metastasis counts with tumor-infiltrating-lymphocyte flow cytometry and histopathology. Where designs called for them, pmel-1 donor-cell arms and TRP-2 peptide vaccine controls were incorporated. Study-specific parameters and outcomes are retained as sponsor-confidential deliverables, and representative outlines can be furnished upon request.

Why Choose Alfa Cytology?

A cold-tumor benchmark only earns the name when its coldness is preserved — Alfa Cytology’s B16-F10-luc service is built around exactly that discipline. Sponsors choosing this platform gain:

• Authenticated CRL-6475 stocks with restricted passage, pigmentation verification, and documented in vivo history.
• Luciferase lines qualified for uniform in vitro glow output before release into studies.
• Three written engraftment routes — intradermal orthotopic, flank, and tail-vein lung-colony — matched to study goals.
• Syngeneic immunocompetent C57BL/6 hosts preserving the complete tumor-immunity axis.
• Integrated companion-reagent workflows including pmel-1 donor cells and TRP-2 peptide controls.
• Dual tumor readouts combining caliper measurements with quantitative bioluminescence.
• Terminal packages combining lung metastasis counts, immune profiling, and histopathology in one report.

Contact Us

Planning a melanoma immunotherapy study in a rigorous cold-tumor setting with imaging-grade readouts? Contact us to discuss engraftment route, checkpoint or vaccine schedule, and endpoint design for the B16-F10 / B16-F10-luc orthotopic platform. You can also reach out to Alfa Cytology for a customized proposal and quotation — our team will respond with a study design built around your immunotherapeutic strategy.

For research use only. Not intended for any clinical use.